Do you routinely use a bone modifying agent in patients with metastatic RCC with bone metastases receiving a TKI?

Agree. For the most part, I don’t use BMA to treat bone mets as there is a lack of data/representation of RCC patients in BMA studies in solid tumors. With that said, I’ve discussed it in selected cases with disseminated bone mets.
Differently, I do offer BMA to treat osteoporosis/osteopenia based o...